Stakeholder Identification
In purusing sustainable development, PharmaEngine deeply understands the importance of stakeholder relations and the continuance of our social commitments. We hope to have a transparent and effective communication channel with our stakeholders. We have identified major stakeholder themes using the following six-step procedure:
Major Themes and Boundaries
Major Theme | SDGs | Management Policy | Border Line | |
Internal | External | |||
Innovative R&D | SDG8 Decent Work and Economic Growth |
|
|
|
Cyber Security | SDG9 Industry, Innovation and Infrastructure |
|
|
|
Corporate Governance | SDG16 Peace, Justice and Strong Institutions SDG17 Partnerships for the Goals |
|
|
|
Industry Cooperation | SDG17 Partnerships for the Goals |
|
|
|
Environment Protection | SDG7 Affordable and Clean Energy SDG12 Responsible Consumption and Production SDG13 Climate Action |
|
|
|
Social Engagement | SDG3 Good Health and Well-Being |
|
|
|
Employee Training | SDG4 Quality Education SDG8 Decent Work and Economic Growth SDG10 Reduced Inequalities |
|
|
|
Stakeholder Communication
PharmaEngine's stakeholders include shareholders (investors), employees, in-license or out-license partners, customers, suppliers & CRO, charity groups, communities, government agencies and media. We aim to maintain good relations with stakeholders when promoting various internal and external matters. As the environment continues to evolve and regulations continue to change, we categorize and assign departments to draft action plans for these major topics to increase the flexibility in communicating with stakeholders through cross-department cooperation. To fulfill the expectations of the stakeholders, we communicate via various channels to ensure the action plans have been properly executed and the communication channels to be free from disruptions. The management team also regularly assess the feedback from stakeholders as a reference for future action plans.
Stakeholder |
Key Issue |
Communication Channel and Frequency |
2023 Engagement |
Shareholders and Investors |
|
|
|
Employees |
|
|
|
In-license or Out-license Partners |
|
|
|
Customers |
|
|
|
Drug Development Partners (Product Storage and Logistics Vendors) |
|
|
|
Supplier |
|
|
|
Community and Charity Groups |
|
|
|
Government Agencies |
|
|
|
Media |
|
|
|
Responses and Responsibilities to Stakeholders
To achieve sustainability, we constantly communicate with stakeholders to understand their needs and use that information as reference of the company policy and business development. We listen to the opinion feedback of the stakeholders as a follow-up to improve the subject during the policy and plan implementation process.
We presented and communicated our "Communication with Stakeholders Report" during the Board of Directors meeting on October 31, 2023. The report covered the purpose of communicating with stakeholders, the major topics of borders, major issues concerning stakeholders, identification of and communication with stakeholders, exchanges with stakeholders, and reflections upon and improvements of communication with stakeholders, etc.
We presented and communicated our "Communication with Stakeholders Report" during the Board of Directors meeting on October 31, 2023. The report covered the purpose of communicating with stakeholders, the major topics of borders, major issues concerning stakeholders, identification of and communication with stakeholders, exchanges with stakeholders, and reflections upon and improvements of communication with stakeholders, etc.
Improvements on Stakeholders' Communication
The Company evaluates annual improvement plans based on company resources and benchmark companies. In 2023, the Company mainly focused improvements on performance evaluations of the Board, Audit Committee, and Remuneration Committee, the independence, competency, and the fee justification of accountants. The Company also regularly report the major topics inquired by the investors and the frequency of communication with stakeholders in the Board meetings.
Stakeholder Contact Information
Stakeholder | Contact Person | Telephone | |
Shareholders and Investors/Media/Government Agencies | Company Spokesperson ChiHsing Chang, Vice President |
(02) 2515-8228 | info@pharmaengine.com |
Employees/Communities and Charity Groups | President & CEO Office, Human Resources Melody Lin, Director |
(02) 2515-8228 | melodylin@pharmaengine.com |
Partnering | Corporate Development, Business Development Roger Hsieh, Associate Director |
(02) 2515-8228 | roger.hsieh@pharmaengine.com |
Drug Development Partners | Research and Development, Medicinal Chemistry & CMC Mel Liu, Ph.D., Associate Director |
(02) 2515-8228 | mel.liu@pharmaengine.com |
Suppliers/Product Storage and Logistics Vendors | President & CEO Office, Quality Assurance Ken Chou, Manager |
(02) 2515-8228 | ken.chou@pharmaengine.com |
Customers | Marketing & Sales, Sales & Product Development April Chiu, Associate Director |
(02) 2515-8228 | april.chiu@pharmaengine.com |
Whistleblower Hotline | Independent Directors/Audit Office | (02) 2515-8228 | audit@pharmaengine.com |